After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan ...

Abcuro appointed former Priovant Therapeutics exec Courtney Cupples as chief commercial officer. Innospera Pharma appointed ...

CAMBRIDGE, MA – Sanjay Seth, a distinguished climate and sustainability expert, has been elected as a new director of the Harvard Alumni Association (HAA), set to begin his three-year term on ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

UK pharma major GSK has appointed Sanjay Gurunathan as senior vice president and global head vaccines and infectious disease ...

Phase III Study on GSK/SPRO’s Oral Antibiotic Stopped Early for Efficacy GSK and partner Spero Therapeutics announced that a phase III study on their oral antibiotic candidate, tebipenem HBr for ...

Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US regulatory authorities to move the treatment forward in 2025. GSK and Spero ...

The drug, called tebipenem HBr, is being developed in partnership with GSK plc GSK. This late-stage study, called PIVOT-PO, enrolled hospitalized adult patients with cUTIs, including ...

Sanjay Goel, MD, MS, professor of medicine at Robert Wood Johnson Medical School and medical oncologist at Rutgers Cancer Institute, anticipates groundbreaking data at the American Society of ...

British drugmaker GSK is preparing for potential new U.S. tariffs on its medicines and can handle the challenge, the company’s leader said Wednesday. “I would say we’ve been preparing ...